Results 21 to 30 of about 264,642 (338)

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Biomedicines, 2021
Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory ...
Xinfang Yu, Wei Li, Ken H. Young, Yong Li   +3 more
doaj   +1 more source

PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy [PDF]

, 2017
Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) can stimulate the immune system.
Azad, Abul, D'Costa, Zenobia, Diana, Angela, Dushek, Omer, Fokas, Emmanouil, Jones, Keaton, Kruger, Philipp, Liu, Stanley, McKenna, W. Gillies, Muschel, Ruth J., Sansom, Owen J., Yin Lim, Su   +11 more
core   +1 more source

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]

, 2016
PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R., Bi, Wenya Linda, Du, Ziming, Dunn, Gavin P, Dunn, Ian F, Fecci, Peter E, Freeman, Gordon J, Greenwald, Noah F, Kaiser, Ursula B, Laws, Edward R, Jr, Mei, Yu, Reardon, David A, Santagata, Sandro, Woodmansee, Whitney W   +13 more
core   +3 more sources

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. [PDF]

, 2020
Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between the presence of anti-PD-1/PD-L1 therapeutic biomarkers and protein markers of potential chemotherapy response.
Arguello, David, Barkauskas, Donald A, Gatalica, Zoran, Kurzrock, Razelle, Nikanjam, Mina, Swensen, Jeff   +5 more
core   +2 more sources

Inhibition of tumor immune escape by blocking PD-1/PD-L1 engagement with dual-targeting molecularly imprinted polymer layer

Cancer Nanotechnology, 2023
Blocking the binding of PD-1/PD-L1 has become an effective strategy in inhibition of tumor immune escape. At present, it mainly depends on the employment of macromolecular antibodies, which target PD-1/PD-L1 protein through binding one of PD-1 or PD-L1 ...
Wenwen Ji, Bei Zhang, Xuetong Sun, Lijuan Ma, Xiangying Zhang, Wenhui Qian, Wenjuan Fu, Jianting Li, Dong Zhu   +8 more
doaj   +1 more source

Overexpression of PD‐L1 causes germ cells to slough from mouse seminiferous tubules via the PD‐L1/PD‐L1 interaction

Journal of Cellular and Molecular Medicine, 2022
AbstractSpermatogenesis is a cyclical process in which different generations of spermatids undergo a series of developmental steps at a fixed time and finally produce spermatids. Here, we report that overexpression of PD‐L1 (B7 homolog1) in the testis causes sperm developmental disorders and infertility in male mice, with severe malformation and ...
Lian Fang, Rui Feng, Weiye Liang, Fang‐Fang Liu, Gan‐lan Bian, Caiyong Yu, Hongmin Guo, Yihui Cao, Mingkai Liu, Jia Zuo, Yinglong Peng, Jie Zhao, Rui‐Xia Sun, Jiajie Shan, Jian Wang   +14 more
openaire   +2 more sources

Imaging PD-L1 Expression with ImmunoPET [PDF]

Bioconjugate Chemistry, 2017
High sensitivity imaging tools could provide a more holistic view of target antigen expression to improve the identification of patients who might benefit from cancer immunotherapy. We developed for immunoPET a novel recombinant human IgG1 (termed C4) that potently binds an extracellular epitope on human and mouse PD-L1 and radiolabeled the antibody ...
Collin M. Blakely, Anna Moroz, Khaled M. Jami, Matthew F.L. Parker, Siok Ping Yeo, Emilie Jaumain, Lawrence Fong, Yung-hua Wang, Hseuh Ling J. Oh, Charles S. Craik, Victor Olivas, Natalia Sevillano, Junnian Wei, Benoit Jego, Charles Truillet, Charles Truillet, Albert J. Chang, Loc T. Huynh, Yuqin S. Shen, Chia Yin Lee, Michael J. Evans, Trever G. Bivona, Cheng-I Wang   +22 more
openaire   +5 more sources

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]

, 2016
A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R, Cane, P, Cree, IA, Gosney, J, Ibrahim, M, Kerr, K, Lal, R, Lewanski, C, Navani, N, Nicholson, AG, Nicolson, M, Summers, Y   +11 more
core   +2 more sources

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]

, 2020
Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin, Eskander, Ramez, Glenn, Sean T, Goodman, Aaron, Ikeda, Sadakatsu, Kato, Shumei, Kumaki, Yuichi, Kurzrock, Razelle, Lee, Suzanna, Lenzo, Felicia L, Morrison, Carl, Nikanjam, Mina, Okamura, Ryosuke, Papanicolau-Sengos, Antonios   +13 more
core   +1 more source

Regulation and Function of the PD-L1 Checkpoint [PDF]

Immunity, 2018
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immunity by counteracting T cell-activating signals. Antibody-based PD-1-PD-L1 inhibitors can induce durable tumor remissions in patients with diverse advanced cancers, and thus ...
Sun, Chong, Mezzadra, Riccardo, Schumacher, Ton N.   +2 more
openaire   +3 more sources